Hexokinase 2 (HK2) (HK2)

Hexokinase 2 (HK2) is a key metabolic enzyme that catalyzes the first step of glucose metabolism by phosphorylating glucose to glucose-6-phosphate. In many cancer types, HK2 is highly overexpressed and specifically localizes to the outer mitochondrial membrane through its interaction with the voltage-dependent anion channel (VDAC) [1][2]. This mitochondrial hexokinase configuration provides the enzyme with direct access to ATP produced by oxidative phosphorylation, facilitating the high glycolytic flux known as the Warburg effect [3]. Beyond its metabolic role, mitochondrial-bound HK2 acts as a potent anti-apoptotic factor by preventing the release of cytochrome c and other pro-apoptotic proteins from the mitochondria [4]. Consequently, HK2 is a major therapeutic target in oncology, with drug development focusing on small molecules that inhibit its catalytic activity or disrupt its mitochondrial attachment to induce metabolic stress and cell death [5]. It is also implicated in metabolic diseases like type 2 diabetes due to its role in insulin-stimulated glucose uptake in muscle and adipose tissues [6]. Targeting HK2 offers a way to selectively impact cancer cells that are heavily dependent on aerobic glycolysis for survival and proliferation [7]. However, potential safety concerns include the impact on normal tissues like the heart and skeletal muscle where HK2 is physiologically active [8].

Other names

HKIIHexokinase type IIMuscle-type hexokinaseMitochondrial hexokinase

Inhibition of glucose phosphorylation and dissociation of the enzyme from the mitochondrial membrane to promote apoptosis.